Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enfuvirtide.

Ray Y Chen1, J Michael Kilby, Michael S Saag

  • 1Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 908 20th Street South, CCB #142, Birmingham, Alabama 35294-2050, USA.

Expert Opinion on Investigational Drugs
|November 30, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort.

AIDS (London, England)·2026
Same author

Factors Associated with Diet Quality in Middle-Aged and Older Adults with HIV: Insights from the PROSPER-HIV study.

medRxiv : the preprint server for health sciences·2026
Same author

Cannabis Use and the Risk of Incident Venous Thromboembolism Among People With HIV: A Longitudinal Cohort Study in the United States.

The Journal of the Association of Nurses in AIDS Care : JANAC·2026
Same author

Complex dynamics between internalized HIV stigma, depression, and anxiety with panic among people with HIV.

AIDS (London, England)·2026
Same author

Associations Between Cannabis Use and Inflammatory Biomarkers Among People with HIV.

Cannabis and cannabinoid research·2026

Enfuvirtide, a new fusion inhibitor, effectively reduces HIV viral load in patients with limited treatment options. Clinical trials show significant virological advantage with minimal side effects, primarily injection site reactions.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Antiretroviral therapy has limitations including drug intolerance and viral resistance.
  • New antiretroviral agents with novel mechanisms are crucial for managing HIV infection.
  • Enfuvirtide represents a new class of antiretroviral drugs: fusion inhibitors.

Purpose of the Study:

  • To evaluate the safety and efficacy of enfuvirtide, a novel fusion inhibitor, in HIV-infected patients.
  • To assess enfuvirtide's role in treatment regimens for patients with limited therapeutic options.

Main Methods:

  • Phase I, II, and III clinical trials were conducted to assess enfuvirtide's safety, pharmacokinetics, and efficacy.
  • Studies compared intravenous, continuous subcutaneous infusion, and intermittent subcutaneous injection regimens.

Related Experiment Videos

  • Randomized trials compared optimized background regimens with or without enfuvirtide.

    • Main Results:

    • Enfuvirtide demonstrated potent in vitro activity and a substantial decline in HIV plasma viral load in Phase I trials.
    • Intermittent subcutaneous injections were pharmacokinetically superior to continuous infusions.
    • Large randomized trials showed a significant virological advantage (approx. 1 log(10) difference) for enfuvirtide plus optimized background therapy at 24 weeks.
    • Minor injection site reactions were common but rarely treatment-limiting; few serious adverse effects were observed.

    Conclusions:

    • Enfuvirtide is a safe and effective addition to HIV treatment regimens, particularly for patients with limited options.
    • The drug's novel mechanism of action as a fusion inhibitor addresses challenges of drug resistance and intolerance.
    • Enfuvirtide is poised to play a significant role in managing complex HIV infections.